" class="no-js "lang="en-US"> Telix Pharmaceuticals - Medtech Alert
Sunday, February 05, 2023

Telix Pharmaceuticals

About Telix Pharmaceuticals

Telix Pharmaceuticals
Telix is a biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).

Related Story

Telix Pharmaceuticals ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU Along with Theranostic Pipeline Advances

December 22 2022

Telix Pharmaceuticals has announced that the completed pivotal Phase III ZIRCON study of TLX250-CDx in […]

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

December 14 2022

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) […]

Telix Announces Executive Leadership Appointments

December 5 2022

Telix Pharmaceuticals has announced several key executive leadership appointments and promotions, reflecting the increased commercial […]

First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy

November 22 2022

Telix Pharmaceuticals has announced that a first patient has been dosed in a Phase II […]

Chinese NMPA Approves Study of Telix Kidney Cancer Imaging Candidate

September 29 2022

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the Chinese National Medical Products […]

Telix and RefleXion Expand Partnership for Prostate Cancer Treatment

June 13 2022

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RefleXion Medical, Inc. (Hayward, California, U.S.) (RefleXion) […]